ThromboGenics´ JETREA® Approved in Switzerland for the Treatment of Vitreomacular Traction
Leuven, March 18, 2014 – ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, today announces that Swissmedic has approved JETREA® (ocriplasmin) for the treatment of adults with vitreomacular traction (VMT), including when associated with macular hole of diameter less than or equal to 400 microns. ThromboGenics’ partner Alcon holds the commercialization rights to JETREA® outside the US and will be responsible for the launch of the drug in Switzerland.
JETREA® is the first pharmacological treatment for this indication and was approved by the European Commission in the European Union in March 2013.
Alcon, a division of Novartis, acquired the rights to commercialize JETREA® outside the United States in March 2012.
Alcon launched the drug in the UK, its first European market, in April 2013. Today, JETREA® is available and reimbursed in the UK, Germany, Denmark, Finland, Norway, Sweden, Ireland, The Netherlands and Canada. First patients have been treated in Belgium, France, Spain and Italy.
ThromboGenics is commercializing the drug in the US and launched JETREA® in the US in mid-January 2013 where it is approved for the treatment of patients with symptomatic vitreomacular adhesion (VMA).
Dr Patrik De Haes, CEO of ThromboGenics, says: “The approval of JETREA® by Swissmedic is another important milestone in the ensuring that JETREA® is available to as many patients as possible. This latest approval confirms our strong belief that JETREA®, in time, will become the treatment of choice for the earlier treatment of patients with VMT.”